加拿大共识推关于广泛阶段小细胞肺癌管理的建议
Barbara L Melosky1, Natasha B Leighl2, David Dawe3
1Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC V5Z 4E6, Canada.
Current oncology (Toronto, Ont.)
|July 28, 2023
概括
本综述提供了针对广泛阶段小细胞肺癌 (SCLC) 治疗的最新共识建议. 它探讨了系统疗法的最新进展,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 医学瘤学 医学瘤学
- 胸部瘤学 胸部瘤学
背景情况:
- 小细胞肺癌 (SCLC) 是一种具有侵略性的神经内分泌瘤,在历史上治疗进展有限.
- 尽管进行了数十年的研究,但SCLC的全身疗法直到最近才取得很小的进展.
- 高复发率和显著的死亡率强调需要改进SCLC管理策略.
研究的目的:
- 审查目前关于广泛阶段SCLC (ES-SCLC) 系统疗法的证据.
- 为ES-SCLC管理制定基于共识的建议.
- 引导临床决策和改善患者的治疗结果.
主要方法:
- 加拿大专家小组将于2022年9月至2023年3月召开会议.
- 文献搜索包括指导方针,系统评论和随机对照试验.
- 讨论的重点是生物标志物,组织学和系统疗法,考虑到患者因素.
主要成果:
- 对一线和随后的全身疗法的证据进行了批判性审查.
- 这些建议涉及ES-SCLC的管理.
- 考虑了患者的表现状况和并发症.
结论:
- 已经建立了ES-SCLC管理的共识建议.
- 这些建议旨在澄清基于证据的实践.
- 目标是促进日常护理中最佳的患者结果.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.3K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cystic Fibrosis: Management
194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
194
